Childhood & Adolescent Disorders

[P495] Treatment for attention-deficit hyperactivity disorder (ADHD) drug normalizes AIS length abnormality along with hyperactivity in pituitary adenylate cyclase-activating polypeptide (PACAP)-deficient mice

*Misaki Iwahashi^1,2, Takeshi Yoshimura¹, Wakana Harigai¹, Kazuhiro Takuma^2,3, Hitoshi Hashimoto^3,4,5,6,7, Taiichi Katayama¹, Atsuko Hayata-Takano^2,3,4 (1. Department of Child Development and Molecular Brain Science, United Graduate School of Child Development, Osaka University, Osaka, Japan, 2. Department of Pharmacology, Graduate School of Dentistry, Osaka University, Osaka, Japan, 3. Molecular Research Center for Children’s Mental Development, United Graduate School of Child Development, Osaka University, Osaka, Japan, 4. Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan, 5. Transdimensional Life Imaging Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan, 6. Division of Bioscience, Institute for Datability Science, Osaka University, Osaka, Japan, 7. Department of Molecular Pharmaceutical Science, Graduate School of Medicine, Osaka University, Osaka, Japan)

Keywords:pituitary adenylate cyclase-activating polypeptide (PACAP), axon initial segment (AIS), atomoxetine (ATX), neurodevelopmental disorder (NDD), attention-deficit/hyperactivity disorder (ADHD)